Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | KIF18A | Q8NI77 | 6/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21143912 | 0.87 | RORC (0.34) | KIF18AMAP4K1NAPEPLDRORC | |
| SCHEMBL20153238 | 0.84 | KMT2A (0.47) | RAF1ADORA2AADORA1KIF18AGAA | |
| SCHEMBL21143838 | 0.81 | CHRM3 (0.38) | RAF1BRAFMTORGAAALDH1A1 | |
| SCHEMBL21144116 | 0.79 | ADORA2A (0.39) | RAF1ADORA2AADORA1KIF18AGAA | |
| SCHEMBL20153235 | 0.78 | ADORA2A (0.50) | RAF1BRAFADORA2AADORA1MTOR | |
| SCHEMBL21143614 | 0.77 | IDH1 (0.37) | RAF1BRAFADORA2AADORA1GAA | |
| SCHEMBL21144147 | 0.77 | EGFR (0.34) | RAF1ADORA2AADORA1MTORGAA | |
| SCHEMBL21144121 | 0.77 | EGFR (0.34) | RAF1ADORA2AADORA1MTORKIF18A | |
| SCHEMBL21143650 | 0.77 | HRH3 (0.36) | RAF1BRAFADORA2AADORA1MTOR | |
| SCHEMBL21144075 | 0.77 | IDH1 (0.44) | RAF1BRAFADORA2AADORA1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380571-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS INC (US) | 2021-12-09 | — | — | US | disclosed |
| EP-3571193-B1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10717728-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190352293-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-11-21 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-10351553-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180215746-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2018-08-02 | — | — | US | disclosed |
| WO-2018136917-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | RAF1 470/4885BRAF 2033/4885ADORA2A 1711/4885 |
| US-20210380571-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK10, KCNJ1 | RAF1 765/4885BRAF 2259/4885ADORA2A 2201/4885 |
| US-10717728-B2 | Potassium channel modulators | KCNJ2, KCNQ2, KCNJ1 | RAF1 641/4885BRAF 1851/4885ADORA2A 1624/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | RAF1 470/4885BRAF 2033/4885ADORA2A 1711/4885 |
| US-20190352293-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK10, KCNJ1 | RAF1 765/4885BRAF 2259/4885ADORA2A 2201/4885 |
| US-20180215746-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK10, KCNJ1 | RAF1 765/4885BRAF 2259/4885ADORA2A 2201/4885 |
| US-10351553-B2 | Potassium channel modulators | KCNN2, KCNN1, KCNN3 | RAF1 521/4885BRAF 1589/4885ADORA2A 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.